SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness - PubMed (original) (raw)
SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness
Autumn Massiello et al. J Lipid Res. 2006 May.
Free article
Abstract
Two splice variants are derived from the caspase-9 gene, proapoptotic caspase-9a and antiapoptotic caspase-9b, by either the inclusion or exclusion of an exon 3, 4, 5, and 6 cassette. Previous studies from our laboratory have shown that the alternative splicing of caspase-9 and the phosphorylation status of SR proteins, a conserved family of splicing factors, are regulated by chemotherapy and ceramide via the action of protein phosphatase-1. In this study, a link between ceramide, SR proteins, and the alternative splicing of caspase-9 was established. The downregulation of SRp30a in A549 cells by RNA interference technology resulted in an increase in the caspase-9b splice variant, with a concomitant decrease in the caspase-9a splice variant, thereby significantly decreasing the caspase-9a/9b ratio from 1.67 +/- 0.11 to 0.56 +/- 0.08 (P < 0.005). The specific downregulation of SRp30a also inhibited the ability of exogenous ceramide treatment to induce the inclusion of the exon 3, 4, 5, and 6 cassette. Therefore, we have identified SRp30a as an RNA trans-acting factor that functions as a major regulator of caspase-9 pre-mRNA processing and is required for ceramide to mediate the alternative splicing of caspase-9.
Similar articles
- De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1.
Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, Hannun YA. Chalfant CE, et al. J Biol Chem. 2002 Apr 12;277(15):12587-95. doi: 10.1074/jbc.M112010200. Epub 2002 Jan 18. J Biol Chem. 2002. PMID: 11801602 - Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD, Chalfant CE. Shultz JC, et al. Cancer Res. 2010 Nov 15;70(22):9185-96. doi: 10.1158/0008-5472.CAN-10-1545. Epub 2010 Nov 2. Cancer Res. 2010. PMID: 21045158 Free PMC article. - SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5' splice site selection of Bcl-x pre-mRNA.
Massiello A, Roesser JR, Chalfant CE. Massiello A, et al. FASEB J. 2006 Aug;20(10):1680-2. doi: 10.1096/fj.05-5021fje. Epub 2006 Jun 21. FASEB J. 2006. PMID: 16790528 - SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A, Hawkins AJ, Mukerjee P, Pinkerman RL, Park MA, Chalfant CE. Shultz JC, et al. Mol Cancer Res. 2011 Jul;9(7):889-900. doi: 10.1158/1541-7786.MCR-11-0061. Epub 2011 May 26. Mol Cancer Res. 2011. PMID: 21622622 Free PMC article. - Identification of two RNA cis-elements that function to regulate the 5' splice site selection of Bcl-x pre-mRNA in response to ceramide.
Massiello A, Salas A, Pinkerman RL, Roddy P, Roesser JR, Chalfant CE. Massiello A, et al. J Biol Chem. 2004 Apr 16;279(16):15799-804. doi: 10.1074/jbc.M313950200. Epub 2004 Jan 20. J Biol Chem. 2004. PMID: 14734550
Cited by
- Alternative mRNA Splicing and Promising Therapies in Cancer.
Fackenthal JD. Fackenthal JD. Biomolecules. 2023 Mar 20;13(3):561. doi: 10.3390/biom13030561. Biomolecules. 2023. PMID: 36979496 Free PMC article. Review. - A Bayesian model for unsupervised detection of RNA splicing based subtypes in cancers.
Wang D, Quesnel-Vallieres M, Jewell S, Elzubeir M, Lynch K, Thomas-Tikhonenko A, Barash Y. Wang D, et al. Nat Commun. 2023 Jan 4;14(1):63. doi: 10.1038/s41467-022-35369-0. Nat Commun. 2023. PMID: 36599821 Free PMC article. - Graphene Oxide Enhances Biogenesis and Release of Exosomes in Human Ovarian Cancer Cells.
Gurunathan S, Kim JH. Gurunathan S, et al. Int J Nanomedicine. 2022 Nov 28;17:5697-5731. doi: 10.2147/IJN.S385113. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36466784 Free PMC article. - Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.
Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, Fabrias G, Desai D, Amin S, Wang HG, Cabot MC, Claxton DF, Kester M, Feith DJ, Loughran TP. Pearson JM, et al. Mol Cancer Res. 2020 Mar;18(3):352-363. doi: 10.1158/1541-7786.MCR-19-0619. Epub 2019 Nov 19. Mol Cancer Res. 2020. PMID: 31744877 Free PMC article. - Expression of the SNAI2 transcriptional repressor is regulated by C16-ceramide.
Lu P, White-Gilbertson S, Nganga R, Kester M, Voelkel-Johnson C. Lu P, et al. Cancer Biol Ther. 2019;20(6):922-930. doi: 10.1080/15384047.2019.1579962. Epub 2019 Mar 5. Cancer Biol Ther. 2019. PMID: 30836822 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials